💡𝗛𝗼𝘄 𝗺𝘂𝗰𝗵 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗰𝗮𝗻 𝗳𝗮𝘀𝘁, 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗺𝗮𝗸𝗲 𝘁𝗼…

Biocartis

48,322 followers

💡𝗛𝗼𝘄 𝗺𝘂𝗰𝗵 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗰𝗮𝗻 𝗳𝗮𝘀𝘁, 𝗮𝗰𝗰𝘂𝗿𝗮𝘁𝗲 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗺𝗮𝗸𝗲 𝘁𝗼 𝗳𝗶𝗿𝘀𝘁-𝗹𝗶𝗻𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀? Professor Jenny Seligmann (Consultant Medical Oncologist, Leeds Teaching Hospitals NHS Trust & Professor of Gastrointestinal Oncology, University of Leeds, UK) explores this question in our on-demand webinar, highlighting why reliable MSI testing remains critical for identifying the right patients for immunotherapy. 𝗔 𝗸𝗲𝘆 𝘁𝗮𝗸𝗲𝗮𝘄𝗮𝘆: "𝘐𝘯 𝘵𝘩𝘦 𝘊𝘩𝘦𝘤𝘬𝘔𝘢𝘵𝘦 8𝘏𝘞 𝘵𝘳𝘪𝘢𝘭, 17% 𝘰𝘧 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘤𝘭𝘢𝘴𝘴𝘪𝘧𝘪𝘦𝘥 𝘢𝘴 𝘥𝘔𝘔𝘙/𝘔𝘚𝘐-𝘏 𝘣𝘺 𝘭𝘰𝘤𝘢𝘭 𝘵𝘦𝘴𝘵𝘪𝘯𝘨 𝘸𝘦𝘳𝘦 𝘳𝘦𝘤𝘭𝘢𝘴𝘴𝘪𝘧𝘪𝘦𝘥 𝘢𝘴 𝘔𝘚𝘚 𝘰𝘯 𝘤𝘦𝘯𝘵𝘳𝘢𝘭 𝘳𝘦𝘵𝘦𝘴𝘵𝘪𝘯𝘨 𝘣𝘺 𝘐𝘥𝘺𝘭𝘭𝘢™. 𝘉𝘶𝘵 𝘸𝘩𝘢𝘵 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘤𝘦 𝘥𝘪𝘥 𝘵𝘩𝘢𝘵 𝘮𝘢𝘬𝘦 𝘵𝘰 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴? 𝘞𝘩𝘦𝘯 𝘵𝘩𝘦 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴 𝘸𝘢𝘴 𝘳𝘦𝘧𝘪𝘯𝘦𝘥 𝘵𝘰 𝘵𝘳𝘶𝘭𝘺 𝘔𝘚𝘐-𝘏 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴, 𝘵𝘩𝘦 𝘰𝘣𝘫𝘦𝘤𝘵𝘪𝘷𝘦 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘦 𝘳𝘢𝘵𝘦 𝘸𝘢𝘴 𝘴𝘪𝘨𝘯𝘪𝘧𝘪𝘤𝘢𝘯𝘵𝘭𝘺 𝘩𝘪𝘨𝘩𝘦𝘳. 𝘛𝘩𝘪𝘴 𝘵𝘦𝘭𝘭𝘴 𝘶𝘴 𝘸𝘦 𝘢𝘳𝘦 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘸𝘩𝘦𝘳𝘦 𝘸𝘦 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘣𝘦 𝘸𝘪𝘵𝘩 𝘢𝘤𝘤𝘶𝘳𝘢𝘵𝘦 𝘵𝘦𝘴𝘵𝘪𝘯𝘨, 𝘢𝘯𝘥 𝘵𝘩𝘢𝘵 𝘨𝘢𝘱 𝘩𝘢𝘴 𝘳𝘦𝘢𝘭 𝘤𝘰𝘯𝘴𝘦𝘲𝘶𝘦𝘯𝘤𝘦𝘴 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘯𝘥 𝘵𝘩𝘦𝘪𝘳 𝘧𝘪𝘳𝘴𝘵-𝘭𝘪𝘯𝘦 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯𝘴." In the webinar, Professor Seligmann also explores: ✔️ Updates to the ESMO mCRC guidelines ✔️ Dual IHC/molecular testing for immunotherapy eligibility ✔️ Emerging biomarker testing strategies in early-stage disease 🎥 𝗪𝗮𝘁𝗰𝗵 𝘁𝗵𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿: https://lnkd.in/eS4p5wfX #ColorectalCancer #CRC #MSI #PrecisionOncology #BiomarkerTesting #CancerDiagnostics #ESMO Idylla™ CDx MSI Test (A0220/6) is CE-marked in Europe in compliance with the EU IVD Regulation 2017/746 (IVDR) and approved in the US under P250005.